NASDAQ : AUTL
Autolus Therapeutics plc — Key statistics
Healthcare · Biotechnology · United Kingdom
Last price 1.52 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 404.57M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 404.57M |
| Enterprise Value | 570.75M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 266.16M |
| Shares Change (YoY) | +2.10% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 0.83% |
| Owned by Institutions (%) | 18.93% |
| Float | 102.92M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.45 |
| Forward PS | 2.49 |
| PB Ratio | 5.41 |
| P/TBV Ratio | 7.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.89 |
| Quick Ratio | 4.06 |
| Debt / Equity | 4.91 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.47 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -133.00% |
| Return on Assets (ROA) | -25.44% |
| Return on Invested Capital (ROIC) | -28.12% |
| Return on Capital Employed (ROCE) | -58.22% |
| Weighted Average Cost of Capital (WACC) | 13.02% |
| Revenue Per Employee | $155,690 |
| Profits Per Employee | -$371,560 |
| Employee Count | 754 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 7.14 |
Taxes
| Measure | Value |
|---|
| Income Tax | 677,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.14 |
| 52-Week Price Change | +4.11% |
| 50-Day Moving Average | 1.91 |
| 200-Day Moving Average | 1.67 |
| Relative Strength Index (RSI) | 36.61 |
| Average Volume (20 Days) | 1,811,343 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.07M |
| Short Previous Month | 8.40M |
| Short % of Shares Out | 5.25% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.63 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 117.39M |
| Gross Profit | -87.58M |
| Operating Income | -247.09M |
| Pretax Income | -279.48M |
| Net Income | -280.16M |
| EBITDA | -236.57M |
| EBIT | -247.09M |
| Loss Per Share | -$1.05 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 201.63M |
| Total Debt | 367.81M |
| Net Cash | -166.18M |
| Net Cash Per Share | -$0.62 |
| Equity (Book Value) | 74.84M |
| Book Value Per Share | 0.28 |
| Working Capital | 267.30M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -225.61M |
| Capital Expenditures | -7.12M |
| Depreciation & Amortization | 10.52M |
| Net Borrowing | n/a |
| Free Cash Flow | -232.73M |
| FCF Per Share | -$0.87 |
Margins
| Measure | Value |
|---|
| Gross Margin | -74.60% |
| Operating Margin | -210.49% |
| Pretax Margin | -238.08% |
| Profit Margin | -238.65% |
| EBITDA Margin | -201.53% |
| EBIT Margin | -210.49% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.10% |
| Shareholder Yield | -2.10% |
| Earnings Yield | -69.25% |
| FCF Yield | -57.53% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.75 |
| Price Target Difference | 475.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 55.48% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -4.39 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |